A vaccine from US company Novavax has been shown to be 89% effective in preventing Covid-19.

Preliminary analysis has shown it to be nearly as effective in protecting against the UK variant, and about 60% against the South African strain. 

The UK has secured 60 million doses of the jab. Here’s what you need to know:

How does the vaccine work?

The Novavax vaccine works like other vaccines by teaching the immune system to make antibodies to the coronavirus spike protein.

Researchers inserted a modified gene into a virus, called a baculovirus, and allowed it to infect insect cells.

Spike proteins from these cells were then assembled into nanoparticles which, while they look like coronavirus, cannot replicate or cause Covid-19.

These nanoparticles are then injected into the body via the vaccine where the immune system mounts an antibody response.

If the body encounters coronavirus in the future, the body is primed to fend it off.

What are its advantages? 

While the jabs from Pfizer/BioNTech and Moderna need to be kept at ultra-low temperatures, the Novavax jab is stable for up to three months in a normal fridge.

The jab should be available in the second half of this year and is being manufactured in Teesside.

 

Was the jab tested in the UK?

Yes. More than 15,000 people in the UK took part in the clinical trial, which was supported by the UK National Institute for Health Research.

Some 27% of those in the UK were over the age of 65.

The study assessed how effective the vaccine was when transmission of Covid-19 was high in the UK, and with the variant strain identified in the UK circulating widely.

The analysis, based on the first 62 cases of Covid-19 identified in the trial, reported 56 cases in people given a placebo (dummy) vaccine while six cases were in those given the vaccine.

More than 50% of cases related to the UK strain of the virus, with the vaccine offering 86% protection against this strain.

Against the original strain that has circulated since the start of the pandemic, the vaccine was 96% effective.

Professor Paul Heath, the Novavax Phase 3 trial chief investigator, said he believed that vaccines could be adapted “at pace” to target new variants of coronavirus.

He told BBC Radio 4’s Today programme that the results from his trial were “yet another great step forward for the UK”.

“I think the technology we have both with this vaccine, the Novavax technology, and the other vaccines, it is such that they can adapt quickly so we can expect to see, if required, new vaccines or bivalent vaccines, where two different strains are joined together in the one vaccine.

“And that now can be done at pace so that we can keep up with these variants should they prove to be difficult to prevent with the vaccine that we have at the moment.

“We’ve seen for the UK that the UK variant can be successfully prevented with this vaccine, which is great.

“Yes, the South African variant is more difficult and hopefully there will not be more variants but we may expect to see some as time goes on.”

What about the South Africa strain?

Data from more than 20,000 people, including a trial in South Africa, has now been reported.

In the South African arm of the trial, where most cases of Covid-19 were the South African strain, the jab was 60% effective in preventing mild, moderate and severe coronavirus among those without HIV.

Including the HIV positive participants, whose immune systems are compromised, overall the protection was just over 49%.

Scientists continue to be concerned about the South African strain of the virus and one that emerged in Brazil, with the expectation that these strains will not work as well with current vaccines.

Novavax plans to immediately begin development on a vaccine specifically targeted to the South African variant.